Carcinoma, Non-Small-Cell Lung study: Amivantamab vs Olomorasib
Official title A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT07227025
What this study is testing
What is Amivantamab?
This is an investigational medicine being studied to see if it helps slow down or prevent the growth of tumors in people with a specific type of lung cancer. It is designed to bind to specific proteins on the surface of cancer cells to help stop them from growing.
Also referred to as RYBREVANT.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find the best dose of amivantamab and olomorasib together and to see if the combo can slow or stop tumor growth.
- Who it's for
- It is looking for adults with metastatic non‑small‑cell lung cancer that has a KRAS G12C mutation.
- What's involved
- Participants will receive the two drugs together, have regular clinic visits, and undergo tests to monitor tumor response and side effects.
- Time commitment
- The study lasts several months, with multiple scheduled visits for drug administration and monitoring.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participant must have histologically or cytologically confirmed metastatic NSCLC characterized by a KRAS G12C mutation at the time of enrollment.
- Participant must have at least 1 measurable lesion, according to RECIST version.1.1, that has not been previously irradiated
- May have brain metastases only if previously definitively, locally treated, and participant is clinically stable and asymptomatic for greater than...
- Can have a prior or concurrent second malignancy (other than the disease under study) with natural history or treatment course that is unlikely to...
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You likely can't join if
- Participant has history of uncontrolled illness
- Suspected or known allergies, hypersensitivity, or intolerance to amivantamab excipients or olomorasib excipients
- Medical history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis...
- Presence of primary driver mutations (epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], mesenchymal-epithelial transition...
- Prior treatment with any KRAS inhibitor
The study team makes the final eligibility decision.
Where it is enrolling
- New York, New York, United States
- Fairfax, Virginia, United States
- Toronto, Ontario, Canada
- Guangzhou, China
- Harbin, China
- Shanghai, China
- Seoul, South Korea
- Ankara, Turkey (Türkiye)
- Çankaya, Turkey (Türkiye)
- Istanbul, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at New York, New York, United States; Fairfax, Virginia, United States; Toronto, Ontario, Canada; Guangzhou, China; Harbin, China; Shanghai, China and 4 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.